Kodiak's Zenkuda and KSI-501 Clear DAYBREAK Endpoint in Wet AMD

Kodiak Sciences cleared the readout it has spent two years building toward: both Zenkuda and its bispecific KSI-501 met their primary endpoints in the DAYBREAK Phase 3 trial in wet age-related macular degeneration.

DAYBREAK was a non-inferiority study running two investigational arms in parallel against aflibercept (Eylea), the market-leading anti-VEGF therapy. At one year, Zenkuda (tarcocimab tedromer) met the non-inferiority bar on vision gains with a p-value of 0.0007, and tabirafusp alfa tedromer (KSI-501) met it with a p-value of 0.0036 and cleared a key retinal-anatomy secondary endpoint at p<0.0001.

The headline is durability. Under strict treat-to-dryness retreatment criteria, 54% of Zenkuda patients reached a 24-week dosing interval at year one, against aflibercept’s standard eight-week schedule and Roche’s Vabysmo at 16 weeks. In retinal disease, fewer injections is the whole contest, and Zenkuda also posted zero intraocular inflammation (0.4% for tabirafusp). The two molecules target the roughly $15 billion anti-VEGF market across retinal vascular disease, where a longer-acting option could reset the standard of care.

Kodiak shares (Nasdaq: KOD) closed Friday at $32.35, a roughly $2 billion market cap; the readout landed before Monday’s open.

The company now plans to file a multi-indication BLA for Zenkuda in the fourth quarter, bundling five Phase 3 studies across wet AMD, diabetic retinopathy and retinal vein occlusion. Zenkuda already delivered positive GLOW1 and GLOW2 data in diabetic retinopathy; wet AMD was the remaining gap, and DAYBREAK fills it. (See our suravec wet AMD primer for the gene-therapy durability angle in this market.)

What to watch next: the Q4 BLA submission and whether the 24-week dosing claim holds up to FDA scrutiny against Vabysmo’s growing franchise.

What It Means for the Trade

Kodiak spent two years building toward this readout, and the prize is a fourth-quarter BLA bundling five Phase 3 studies across wet AMD, diabetic retinopathy and retinal vein occlusion — a filing that turns the company from a single-asset story into a multi-indication franchise application. The durability claim is the commercial weapon: 54% of Zenkuda patients held a 24-week dosing interval at year one under strict treat-to-dryness retreatment, against aflibercept’s eight-week schedule and Vabysmo’s 16 weeks. In a $15 billion market where injection burden drives real-world under-treatment, a label that lets even a subset of patients halve their clinic visits resets the standard of care. At a roughly $2 billion market cap, the stock has not yet traded the news — the readout landed before Monday’s open — so the first session is the repricing event, and the level it sets will say whether the market believes the 24-week claim is label-worthy.

Filing both molecules strengthens the story. KSI-501’s parallel success gives Kodiak a second act with its own retinal-anatomy data, hedging the franchise against any single-molecule regulatory surprise, and the non-inferiority margins — p-values of 0.0007 and 0.0036 — leave little statistical ambiguity. Zenkuda had already banked GLOW1 and GLOW2 in diabetic retinopathy; DAYBREAK was the remaining gap, and it filled.

Mechanism and Trial Context

The tedromer format is the design: Kodiak tethers an anti-VEGF payload to an albumin-binding polymer, extending the molecule’s residence in the eye so the drug keeps working long after the injection. Durability in retinal disease is a pharmacokinetic problem before it is a biology problem, and DAYBREAK tested it honestly — treat-to-dryness retreatment is conservative, meaning patients were re-injected when disease activity showed, not on a calendar that flatters the drug. Zero intraocular inflammation in the Zenkuda arm is not a footnote; ocular inflammation has been the failure mode for earlier attempts at longer-acting agents, and a clean profile is what makes a 24-week interval claim look plausible to a reviewer rather than aspirational. The competitive pressure runs in both directions: Vabysmo keeps expanding from its 16-week position, cheap biosimilar aflibercept undercuts the price of the old standard of care, and durable gene-therapy approaches define the ceiling on how long any injected drug stays the answer.

Risks and What Could Go Wrong

1. The FDA may not translate trial durability into label language — a 24-week dosing interval claim must survive review, and regulators have historically been conservative about label claims that stretch beyond studied regimens.
2. A five-study BLA is a heavy package; complexity invites complete-response risk or a stretched review even with clean data.
3. Biosimilar aflibercept keeps getting cheaper, compressing the premium a longer-acting brand can charge at the margin.
4. KSI-501’s 0.4% inflammation rate is low but nonzero — a signal that grows in the real world would dent the bispecific’s case.